In human cancer cell-lines with defective function of BRCA1, PALB2 or BRCA2, RAD52′s depletion increases damage-associated chromosomal abnormalities, decreases clonal viability, and also reduces the HR activity [28,30]. This evidence concerns the gene BRCA2 and cancer.